Arbiter Settles Santaris-Exiqon LNA Dispute; Each Firm Claims Victory | GenomeWeb

By Doug Macron

Santaris Pharma and Exiqon announced last week that an arbiter has settled their legal battle over rights to market locked nucleic acid amidites and oligos, a move that prompted both firms to claim a measure of victory.

According to Exiqon, the Danish court has ruled it is permitted to sell the amidites and oligos to companies conducting research and development of pharmaceuticals in which LNAs are the active ingredient — an issue that was in dispute.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.